vorinostat has been researched along with Hematologic Malignancies in 16 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
| Excerpt | Relevance | Reference |
|---|---|---|
| " The Food and Drug Administration has approved two HDAC inhibitors, vorinostat (2006) and romidepsin (2009), for the treatment of cutaneous T-cell lymphoma." | 8.93 | The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: A review of clinical studies. ( Dimopoulos, M; Duvic, M, 2016) |
| " The Food and Drug Administration has approved two HDAC inhibitors, vorinostat (2006) and romidepsin (2009), for the treatment of cutaneous T-cell lymphoma." | 4.93 | The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: A review of clinical studies. ( Dimopoulos, M; Duvic, M, 2016) |
| "To determine the safety, dosing schedules, pharmacokinetic profile, and biologic effect of orally administered histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) in patients with advanced cancer." | 2.71 | Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. ( Chiao, JH; Chu, E; Curley, T; Heaney, M; Kelly, WK; Krug, LM; MacGregore-Cortelli, B; Marks, PA; O'Connor, OA; Olgac, S; Richardson, S; Richon, VM; Scher, H; Schwartz, L; Secrist, JP; Tong, W, 2005) |
| "Vorinostat was approved in the United States in 2006 for the treatment of cutaneous manifestations of T-cell lymphoma in patients with progressive, persistent, or recurrent disease on or following 2 systemic therapies." | 2.46 | The role of histone deacetylase inhibitors in the treatment of patients with cutaneous T-cell lymphoma. ( Hymes, KB, 2010) |
| "Therefore, in this review we focus upon hematologic malignancies." | 2.45 | Clinical studies of histone deacetylase inhibitors. ( Bishton, MJ; Harrison, SJ; Prince, HM, 2009) |
| "When vorinostat was combined with antioxidant agents, the apoptosis of MPN cells increased in a synergistic manner." | 1.51 | Vorinostat synergizes with antioxidant therapy to target myeloproliferative neoplasms. ( Almeida, AM; Belo, H; Cardoso, BA; Ramos, TL; Real, C; Vilas-Boas, F, 2019) |
| "A total of 39 patients with hematologic malignancy were enrolled (14 on IV SAHA and 25 on oral SAHA), of whom 35 were treated." | 1.33 | Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. ( Curly, T; Frankel, S; Heaney, ML; Horwitz, S; Kelly, WK; MacGregor-Cortelli, B; Marks, P; Moskowitz, C; O'Connor, OA; Portlock, C; Richardson, S; Richon, V; Schwartz, L; Willim, R; Zelenetz, AD, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (43.75) | 29.6817 |
| 2010's | 8 (50.00) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Yang, EG | 1 |
| Mustafa, N | 1 |
| Tan, EC | 1 |
| Poulsen, A | 1 |
| Ramanujulu, PM | 1 |
| Chng, WJ | 1 |
| Yen, JJ | 1 |
| Dymock, BW | 1 |
| Liang, X | 1 |
| Zang, J | 1 |
| Li, X | 1 |
| Tang, S | 1 |
| Huang, M | 1 |
| Geng, M | 1 |
| Chou, CJ | 1 |
| Li, C | 1 |
| Cao, Y | 1 |
| Xu, W | 1 |
| Liu, H | 1 |
| Zhang, Y | 2 |
| Lu, D | 1 |
| Wang, C | 1 |
| Qu, L | 1 |
| Yin, F | 1 |
| Li, S | 1 |
| Luo, H | 1 |
| Liu, X | 1 |
| Chen, X | 1 |
| Luo, Z | 1 |
| Cui, N | 1 |
| Kong, L | 1 |
| Wang, X | 1 |
| Hoodin, F | 1 |
| LaLonde, L | 1 |
| Errickson, J | 1 |
| Votruba, K | 1 |
| Kentor, R | 1 |
| Gatza, E | 1 |
| Reddy, P | 1 |
| Choi, SW | 1 |
| Cardoso, BA | 1 |
| Ramos, TL | 1 |
| Belo, H | 1 |
| Vilas-Boas, F | 1 |
| Real, C | 1 |
| Almeida, AM | 1 |
| Duvic, M | 2 |
| Dimopoulos, M | 1 |
| Min, HY | 1 |
| Lee, SC | 1 |
| Woo, JK | 1 |
| Jung, HJ | 1 |
| Park, KH | 1 |
| Jeong, HM | 1 |
| Hyun, SY | 1 |
| Cho, J | 1 |
| Lee, W | 1 |
| Park, JE | 1 |
| Kwon, SJ | 1 |
| Lee, HJ | 1 |
| Ni, X | 1 |
| Shin, YK | 1 |
| Johnson, FM | 1 |
| Lee, HY | 1 |
| Furukawa, Y | 1 |
| Prince, HM | 1 |
| Bishton, MJ | 1 |
| Harrison, SJ | 1 |
| Stimson, L | 1 |
| Wood, V | 1 |
| Khan, O | 1 |
| Fotheringham, S | 1 |
| La Thangue, NB | 1 |
| Siegel, D | 1 |
| Hussein, M | 1 |
| Belani, C | 1 |
| Robert, F | 1 |
| Galanis, E | 1 |
| Richon, VM | 3 |
| Garcia-Vargas, J | 1 |
| Sanz-Rodriguez, C | 1 |
| Rizvi, S | 1 |
| Hymes, KB | 1 |
| Newbold, A | 1 |
| Vervoort, SJ | 1 |
| Martin, BP | 1 |
| Bots, M | 1 |
| Johnstone, RW | 1 |
| Kelly, WK | 3 |
| O'Connor, O | 1 |
| Curley, T | 2 |
| MacGregor-Curtelli, B | 1 |
| Tong, W | 2 |
| Klang, M | 1 |
| Schwartz, L | 3 |
| Richardson, S | 3 |
| Rosa, E | 1 |
| Drobnjak, M | 1 |
| Cordon-Cordo, C | 1 |
| Chiao, JH | 2 |
| Rifkind, R | 1 |
| Marks, PA | 2 |
| Scher, H | 2 |
| O'Connor, OA | 2 |
| Krug, LM | 1 |
| Heaney, M | 1 |
| MacGregore-Cortelli, B | 1 |
| Secrist, JP | 1 |
| Chu, E | 1 |
| Olgac, S | 1 |
| Heaney, ML | 1 |
| Willim, R | 1 |
| MacGregor-Cortelli, B | 1 |
| Curly, T | 1 |
| Moskowitz, C | 1 |
| Portlock, C | 1 |
| Horwitz, S | 1 |
| Zelenetz, AD | 1 |
| Frankel, S | 1 |
| Richon, V | 1 |
| Marks, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Cognitive Function and Patient-Reported Psychological and Functional/Quality of Life Outcomes Investigation in Patients Taking Vorinostat for Graft-versus-Host Disease Prophylaxis[NCT02409134] | 9 participants (Actual) | Observational | 2015-04-30 | Completed | |||
| A Randomized Study to Compare the Efficacy of Vorinostat/Hydroxychloroquine/Maraviroc (VHM) in Controlling HIV After Treatment Interruption in Subjects Who Initiated ART During Acute HIV Infection[NCT02475915] | Phase 1/Phase 2 | 15 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| Phase I/II Clinical Trial of Vorinostat in Patients With Recurrent and/or Metastatic Breast Cancer[NCT00416130] | Phase 1/Phase 2 | 49 participants (Anticipated) | Interventional | 2007-01-31 | Active, not recruiting | ||
| IGHID 11424 - A Pilot Trial of the Effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection (The VOR VAX Study)[NCT02707900] | Phase 1 | 6 participants (Actual) | Interventional | 2016-03-31 | Terminated (stopped due to Manufacturing of the AGS-004 HIV vaccine by Argos could no longer be provided.) | ||
| Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft Tissue Sarcoma After Pre-treatment Failure: an Open-label, Multicenter Phase II Study[NCT01136499] | Phase 2 | 53 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for vorinostat and Hematologic Malignancies
| Article | Year |
|---|---|
The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: A review of clinical studies.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Depsipeptides; Disease Management; Hematologic Neoplas | 2016 |
[Epigenetics in hematological disorders].
Topics: Antineoplastic Agents; Azacitidine; Depsipeptides; DNA Methylation; Drug Design; Enzyme Inhibitors; | 2008 |
Clinical studies of histone deacetylase inhibitors.
Topics: Antibiotics, Antineoplastic; Benzamides; Clinical Trials as Topic; Depsipeptides; Drug Therapy, Comb | 2009 |
HDAC inhibitor-based therapies and haematological malignancy.
Topics: Enzyme Inhibitors; Hematologic Neoplasms; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; | 2009 |
Vorinostat in solid and hematologic malignancies.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Hem | 2009 |
The role of histone deacetylase inhibitors in the treatment of patients with cutaneous T-cell lymphoma.
Topics: Antineoplastic Agents; Depsipeptides; Hematologic Neoplasms; Histone Deacetylase Inhibitors; Humans; | 2010 |
3 trials available for vorinostat and Hematologic Malignancies
| Article | Year |
|---|---|
Cognitive Function and Quality of Life in Vorinostat-Treated Patients after Matched Unrelated Donor Myeloablative Conditioning Hematopoietic Cell Transplantation.
Topics: Adult; Aged; Allografts; Autografts; Cognition; Female; Hematologic Neoplasms; Hematopoietic Stem Ce | 2019 |
Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.
Topics: Acetylation; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Bi | 2003 |
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Biological Availability; Drug Administration Schedule; Enzyme Inh | 2005 |
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Biological Availability; Drug Administration Schedule; Enzyme Inh | 2005 |
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Biological Availability; Drug Administration Schedule; Enzyme Inh | 2005 |
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Biological Availability; Drug Administration Schedule; Enzyme Inh | 2005 |
7 other studies available for vorinostat and Hematologic Malignancies
| Article | Year |
|---|---|
Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines.
Topics: Antineoplastic Agents; Apoptosis; Bridged-Ring Compounds; Cell Line, Tumor; Cell Proliferation; Hema | 2016 |
Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies.
Topics: Animals; Binding Sites; Catalytic Domain; Drug Evaluation, Preclinical; Half-Life; Hematologic Neopl | 2019 |
Histone Deacetylase and Enhancer of Zeste Homologue 2 Dual Inhibitors Presenting a Synergistic Effect for the Treatment of Hematological Malignancies.
Topics: Cell Line, Tumor; Cell Proliferation; Enhancer of Zeste Homolog 2 Protein; Epigenesis, Genetic; Hema | 2022 |
Vorinostat synergizes with antioxidant therapy to target myeloproliferative neoplasms.
Topics: Adult; Aged; Antioxidants; Apoptosis; Cell Line, Tumor; Drug Synergism; Female; Hematologic Neoplasm | 2019 |
Essential Role of DNA Methyltransferase 1-mediated Transcription of Insulin-like Growth Factor 2 in Resistance to Histone Deacetylase Inhibitors.
Topics: Animals; CCCTC-Binding Factor; DNA (Cytosine-5-)-Methyltransferase 1; DNA Methylation; Drug Resistan | 2017 |
Induction of autophagy does not alter the anti-tumor effects of HDAC inhibitors.
Topics: Animals; Apoptotic Protease-Activating Factor 1; Autophagy; Autophagy-Related Protein 5; Autophagy-R | 2012 |
Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Enzyme Inhibitors; Fema | 2006 |